Pharmascience Inc. Launches (Pr)pms-NITROFURANTOIN, First Generic Bioequivalent to MacroBID® Available on the Market, for the Treatment of Urinary Tract Infections
MONTREAL, May 14, 2018 /CNW/ - Today, Pharmascience Inc. launches Prpms-NITROFURANTOIN (nitrofurantoin monohydrate / macrocrystals capsules) in Canada for the treatment of urinary tract infections.
"With the launch of Prpms-NITROFURANTOIN, manufactured in Canada, we become the first generic bioequivalent to MacroBID® on the Canadian market," said Jean-Guy Goulet, Chief Operating Officer at Pharmascience Inc.
Prpms-NITROFURANTOIN is indicated for the treatment of patients suffering from acute, uncomplicated urinary tract infections, e.g. cystitis, when due to susceptible strains of Escherichia coli and Staphylococcus saprophyticus.1
One in two women will suffer from a urinary tract infection at least once in their lifetime. Most urinary tract infections are caused by bacteria.2
"The launch of this product is a prime example of Pharmascience's commitment to offering Canadians effective and accessible treatments," added Mr. Goulet.
About Pharmascience Inc.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 51st among Canada's top 100 Research & Development (R&D) investors with over $49 million invested in 2016, Pharmascience Inc. is the 3rd largest manufacturer of over-the-counter generic drugs in the country.
Pharmascience Inc. is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. The company commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.
In 2018, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine. Pharmascience's total donations of essential medicine is close to $67 million.
For more information, please visit www.pharmascience.com.
References: 1. Prpms-NITROFURANTOIN product monograph. Pharmascience Inc. June 7, 2016.
2. The College of Family Physicians of Canada: Urinary Tract Infections--A common problem for some women. http://www.cfpc.ca/projectassets/templates/resource.aspx?id=3809&langType=4105.
Consulted: May 8, 2018
For all media requests: Steeve Azoulay, Senior Director, Public Affairs and Communications, Tel.: 514-340-9800, ext. 7696, email@example.com
SOURCE Pharmascience Inc.